Literature DB >> 2478654

Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation.

I Berkower1, G E Smith, C Giri, D Murphy.   

Abstract

HIV-1 is known to show a high degree of genetic diversity, which may have major implications for disease pathogenesis and prevention. If every divergent isolate represented a distinct serotype, then effective vaccination might be impossible. However, using a sensitive new plaque-forming assay for HIV-1, we have found that most infected patients make neutralizing antibodies, predominantly to a group-specific epitope shared among three highly divergent isolates. This epitope persists among divergent isolates and rarely mutates, despite the rapid overall mutation rate of HIV-1, suggesting that it may participate in an essential viral function. These findings, plus the rarity of reinfections among these patients, suggest that HIV-1 may be more susceptible to a vaccine strategy based on a group-specific neutralizing epitope than was previously suspected.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478654      PMCID: PMC2189498          DOI: 10.1084/jem.170.5.1681

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  37 in total

1.  A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus.

Authors:  R DULBECCO; M VOGT; A G STRICKLAND
Journal:  Virology       Date:  1956-04       Impact factor: 3.616

2.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

4.  Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire.

Authors:  S Benn; R Rutledge; T Folks; J Gold; L Baker; J McCormick; P Feorino; P Piot; T Quinn; M Martin
Journal:  Science       Date:  1985-11-22       Impact factor: 47.728

5.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

6.  The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype).

Authors:  A J Caton; G G Brownlee; J W Yewdell; W Gerhard
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

7.  A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB.

Authors:  J Albert; U Bredberg; F Chiodi; B Böttiger; E M Fenyö; E Norrby; G Biberfeld
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

8.  Expression of the HTLV-III envelope gene by a recombinant vaccinia virus.

Authors:  S Chakrabarti; M Robert-Guroff; F Wong-Staal; R C Gallo; B Moss
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

9.  Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies.

Authors:  W Gerhard; J Yewdell; M E Frankel; R Webster
Journal:  Nature       Date:  1981-04-23       Impact factor: 49.962

Review 10.  Retroviruses.

Authors:  H Varmus
Journal:  Science       Date:  1988-06-10       Impact factor: 47.728

View more
  19 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

Authors:  C Y Kang; P Nara; S Chamat; V Caralli; T Ryskamp; N Haigwood; R Newman; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

3.  Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.

Authors:  R Wyatt; M Thali; S Tilley; A Pinter; M Posner; D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

4.  Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.

Authors:  N L Haigwood; P L Nara; E Brooks; G A Van Nest; G Ott; K W Higgins; N Dunlop; C J Scandella; J W Eichberg; K S Steimer
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.

Authors:  N Sullivan; M Thali; C Furman; D D Ho; J Sodroski
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

6.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  Neutralizing antibodies in cats infected with feline immunodeficiency virus.

Authors:  F Tozzini; D Matteucci; P Bandecchi; F Baldinotti; K Siebelink; A Osterhaus; M Bendinelli
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

8.  Tissue infiltration in a CD8 lymphocytosis syndrome associated with human immunodeficiency virus-1 infection has the phenotypic appearance of an antigenically driven response.

Authors:  S Itescu; J Dalton; H Z Zhang; R Winchester
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.

Authors:  R Wyatt; N Sullivan; M Thali; H Repke; D Ho; J Robinson; M Posner; J Sodroski
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.

Authors:  M S Fung; C R Sun; W L Gordon; R S Liou; T W Chang; W N Sun; E S Daar; D D Ho
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.